EGFR and non-small cell lung carcinoma: Additionally, the LAURA trial (NCT03521154) showed that in patients with unresectable stage III EGFR-mutant NSCLC who had received definitive chemoradiotherapy, osimertinib significantly prolonged PFS compared with placebo[22,23].